Sitting Down With… Tom Moody, VP of Technology Development and Commercialization at Almac, Craigavon, UK.
Maryam Mahdi |
This article was published in our sister publication, The Small Molecule Manufacturer, which celebrates the field of small molecule drug development and manufacturing with interviews and articles focusing on success stories, equipment, and new processing techniques. Read more about The Small Molecule Manufacturer here https://themedicinemaker.com/manufacture/small-but-never-forgotten
Has science always been a passion?
Science was always one of my favorite subjects at school. Initially, I loved the idea of just mixing things together, but as I grew I also came to appreciate the practical side of it. I was fascinated by how science could be applied to solve problems – especially when it came to chemistry. My passion pushed me to pursue a degree in chemistry and that is where I began to excel; I was proud to graduate from Queen’s University Belfast, with the top grades in my year group and subsequent completion of a PhD.
What other interests have you pursued?
I’ve always been interested in the ways that businesses operate and, as I started work in the pharma industry, I wanted to understand how pharmaceutical companies, as commercial entities, were able to invest, reinvest and grow. I joined Almac in 2001 and quickly became a team leader. But I wanted to differentiate myself from others working in the organic chemistry department and bring value to the business. I realized I could only do that by offering up ideas and solutions that could have a meaningful impact on the company’s future. Was there a technology that I could help introduce that could have benefits for the company? Or were there other avenues, yet to be considered, that were worth exploring?
In 2003, I decided to pursue a masters in business alongside my work at Almac to help improve my knowledge of the commercial world. During that period of time, I began to develop a business plan outlining the benefits of biocatalysis for Almac. I presented it to the senior management team, which must have gone well, because they allowed me to begin developing the technology.
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE and always will be!
Or register now - it’s free and always will be!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine
Or Login via Social Media
By clicking on any of the above social media links, you are agreeing to our Privacy Notice.